CLEVEXEL PHARMA has a total of 29 patent applications. It decreased the IP activity by 88.0%. Its first patent ever was published in 2012. It filed its patents most often in EPO (European Patent Office), Australia and Brazil. Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are SUNSHINE LAKE PHARMA CO LTD, KBP BIOSCIENCES CO LTD and UNIV CHANG GUNG SCIENCE & TECHNOLOGY.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 4 | |
#2 | Australia | 3 | |
#3 | Brazil | 3 | |
#4 | Canada | 3 | |
#5 | Mexico | 3 | |
#6 | China | 2 | |
#7 | Israel | 2 | |
#8 | United States | 2 | |
#9 | WIPO (World Intellectual Property Organization) | 2 | |
#10 | South Africa | 2 | |
#11 | Hong Kong | 1 | |
#12 | Hungary | 1 | |
#13 | Republic of Korea | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Name | Total Patents |
---|---|---|
#1 | Gonzalez Karine | 8 |
#2 | Deutsch Eric | 8 |
#3 | Pivette Perrine | 8 |
#4 | Bricout Denis | 7 |
#5 | Wang-Zhang Xiuping | 7 |
#6 | Behar Vered | 5 |
#7 | Mirilashvili Sima | 5 |
#8 | Konson Alexander | 5 |
#9 | Yacovan Avihai | 5 |
#10 | Wang Ép Zhang Xiuping | 5 |
Publication | Filing date | Title |
---|---|---|
AU2016374382A1 | Pulsatile release pharmaceutical composition comprising naftazone or one of its salts | |
EP3330251A1 | Process for the preparation of freeze-dried 2-[(3-aminopropyl)amino]ethanethiol | |
MX2013014433A | Compositions and methods for modulating a kinase. |